CTOs on the Move

GrowBLOX Sciences

www.growblox.com

 
GrowBLOX Sciences (OTCQ GBLX) – merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients in communities across the country.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.growblox.com
  • 6450 Cameron St. Ste 110
    Las Vegas, NV USA 89118
  • Phone: 866.721.0297

Executives

Name Title Contact Details

Similar Companies

Tasso

Tasso is changing the way that care is delivered with simple, virtually painless, clinical-grade diagnostic testing that can be done from home.

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.

AbSci

AbSci is a global leader in biomanufacturing technologies. The company`s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes.

Omnicia

Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.